Name | LR-90 |
Description | LR-90, an advanced glycation end product (AGE) inhibitor, is utilized in diabetic animal model research. This compound effectively suppresses inflammatory responses in human monocytes. |
In vitro | LR-90 (0, 25, 50, 100, and 200 μM) significantly blocks THP-1 cell adherence to endothelial cells in a dose-dependent manner after 1-hour pretreatment followed by S100b stimulation for 24 hours, without affecting THP-1 cell viability. Additionally, LR-90 inhibits RAGE, MCP-1, COX-2, IP-10, and NOX2 mRNA expression in THP-1 cells dose-dependently after 1-hour pretreatment before S100b stimulation for 4 hours[1]. |
In vivo | LR-90 (50 mg/L) decreases renal AGE, AGER and lipid peroxidation[2].LR-90 (50 mg/L, p.o. for 27 weeks) significantly reduces plasma lipids, modestly affects hyperglycaemia in ZDF rats[2]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 95 mg/mL (133.88 mM)
|
Keywords | inhibit | LR90 | LR-90 | Inhibitor | LR 90 |
Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library |